Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

PloS one - 1 Jan 2012

Guyader Charlotte, Céraline Jocelyn, Gravier Eléonore, Morin Aurélie, Michel Sandrine, Erdmann Eva, de Pinieux Gonzague, Cabon Florence, Bergerat Jean-Pierre, Poupon Marie-France, Oudard Stéphane

Abstract excerpt

Almost all prostate cancers respond to androgen deprivation treatment but many recur. We postulated that risk of hormone escape--frequency and delay--are influenced by hormone therapy modalities. More, hormone therapies induce crucial biological changes involving androgen receptors; some might be targets for escape prevention. We investigated the relationship between the androgen deprivation treatment and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgens
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Gene Dosage

Share to Protein-Tyrosine Kinases

Share to Receptor, ErbB-2

Share to Receptors, Androgen

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 22879924
DOI: 10.1371/journal.pone.0042252
PMCID: PMC3412862

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.PMID 22879924Read ↗

Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerSemantic proximity Read ↗

[Mechanisms of prostate cancer recurrence].Semantic proximity Read ↗

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.Semantic proximity Read ↗

Therapy escape mechanisms in the malignant prostate.Semantic proximity Read ↗

How the Management of Biochemical Recurrence in Prostate Cancer Will be Modified by the Concept of Anticipation and Incrementation of TherapySemantic proximity Read ↗

Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.Semantic proximity Read ↗

[Hormone Resistance and Neuroendocrine Differentiation Due to Accumulation of Genetic Lesions during Clonal Evolution of Prostate Cancer].Semantic proximity Read ↗

Androgen receptor action in hormone-dependent and recurrent prostate cancer.Semantic proximity Read ↗

[Metastatic castration-resistant prostate cancer-emerging trends in therapy].Semantic proximity Read ↗

Glucocorticoid signaling delays castration-induced regression in murine models of prostate cancerSemantic proximity Read ↗

Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancerSemantic proximity Read ↗

Identification of differentially expressed genes associated with androgen‐independent growth of prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.